Compare SGC & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGC | CGEN |
|---|---|---|
| Founded | 1920 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.8M | 191.1M |
| IPO Year | 1994 | 2001 |
| Metric | SGC | CGEN |
|---|---|---|
| Price | $12.88 | $2.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $16.00 | $5.00 |
| AVG Volume (30 Days) | 30.9K | ★ 184.2K |
| Earning Date | 05-04-2026 | 05-18-2026 |
| Dividend Yield | ★ 4.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $566,184,000.00 | N/A |
| Revenue This Year | $3.23 | N/A |
| Revenue Next Year | $3.82 | $75.09 |
| P/E Ratio | $89.79 | ★ N/A |
| Revenue Growth | ★ 0.09 | N/A |
| 52 Week Low | $8.30 | $1.38 |
| 52 Week High | $14.59 | $3.24 |
| Indicator | SGC | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 55.00 | 43.55 |
| Support Level | $11.72 | $2.34 |
| Resistance Level | $12.83 | $2.54 |
| Average True Range (ATR) | 0.40 | 0.08 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 87.20 | 23.44 |
Superior Group Of Companies Inc designs apparel products. The company operates through three segments: i) The Branded Products segment, under the brands BAMKO and HPI, produces and sells customized merchandising solutions, promotional products, and branded uniform programs. ii) The Healthcare Apparel segment, under the brands Wink and Fashion Seal Healthcare, manufactures and sells healthcare apparel including scrubs, lab coats, protective apparel, and patient garments. iii) The Contact Centers segment, through The Office Gurus entities, provides outsourced, nearshore, and onshore business process outsourcing (BPO), contact center, and call-center support services to customers in North America. The majority of the company's revenue is derived from the Branded Products segment.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.